Vorasidenib 40mg tablets
NHS hospitals in England used £17,297,000 of indicative cost of Vorasidenib 40mg tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 0.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Vorasidenib 40mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Vorasidenib 40mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Royal Marsden Nhs Foundation Trust | £4,267,500 |
| The Christie Nhs Foundation Trust | £2,004,500 |
| East And North Hertfordshire Nhs Trust | £1,353,000 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £1,282,500 |
| The Clatterbridge Cancer Centre Nhs Ft | £1,072,500 |
| Barts Health Nhs Trust | £976,500 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £973,500 |
| Oxford University Hospitals Nhs Ft | £808,500 |
| Western Sussex Hospitals Nhs Found Trust | £676,500 |
| University College London Foundation Tr | £594,000 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.